1 hr. ago
Bruker (NASDAQ:BRKR) returned to organic revenue growth in the second quarter, posted stronger bookings across its Scientific Instruments business, and maintained its earnings outlook while adjusting guidance for currency and tax changes.
Bruker (NASDAQ:BRKR) returned to organic revenue growth, with second-quarter revenue increasing 5.2% to $838.5 million.
Scientific Instruments bookings rose 10% organically, with a book-to-bill ratio above 1.0x, pointing to continued order momentum.
Non-GAAP EPS increased to $0.49 as operating margins improved despite a GAAP loss driven by a non-cash goodwill impairment charge.
Management updated its 2026 outlook for currency and tax impacts while maintaining expectations for double-digit non-GAAP EPS growth.
#bruker #scientific #instruments #returned
Bruker (NASDAQ:BRKR) returned to organic revenue growth, with second-quarter revenue increasing 5.2% to $838.5 million.
Scientific Instruments bookings rose 10% organically, with a book-to-bill ratio above 1.0x, pointing to continued order momentum.
Non-GAAP EPS increased to $0.49 as operating margins improved despite a GAAP loss driven by a non-cash goodwill impairment charge.
Management updated its 2026 outlook for currency and tax impacts while maintaining expectations for double-digit non-GAAP EPS growth.
#bruker #scientific #instruments #returned
